Table of Contents
Week 01: Medical Technology Assessment Environment Quiz Answers
Q1. Which of the following is a use a potential user of medical technology evaluation results?
- Manufacturers.
- Insurers.
- Health care providers.
- All of the above.
Q2. True or False: A medical technology evaluation is just a pricing project.
- True
- False
Q3. How can a new technology with lower costs lead to higher health care expenditures?
- The technology will only reduce expenditures.
- The technology is effective and used by a larger population than the current technology.
- No new technologies have lower costs.
- The technology has better outcomes compared to the current technology.
Q4. What is the regulatory reason that medical technology evaluation evidence is needed?
- Only payment/reimbursement.
- Venture capitalist investments.
- Pricing.
- Marketing approval and payment/reimbursement.
Q5. Which of the FDA approval phases occurs after FDA approval?
- Phase IV
- Phase III and IV
- None
- Phase I
Q6. True or False: Once approved a new drug can only be prescribed for what it was approved to treat.
- True
- False
Q7. Approximately what percent of new medical devices require a Pre-Market Approval (PMA)?
- 0 percent
- 100 percent
- 90 percent
- 10 percent
Q8. What is the next step after a drug is approved by the FDA?
- File an NDA.
- Conduct a clinical trial.
- Get insurers to pay/reimburse.
- Design the packaging.
Q9. What aspects of medical care is covered by Medicare Part A?
- Outpatient services.
- Inpatient hospital care.
- Prescription drugs.
- Patient out-of-pocket costs.
Q10. True or False: Patients may have higher cost-sharing obligations for the more expensive brand name version of a drug.
- True
- False
Week 02: Clinical Trials and Insurance Claims Data Quiz Answers
Q1. following is an example of an experimental design?
- Patient survey
- Case study
- Observational study
- Randomized controlled trial
Q2. Which of the following is not an alternative to randomization?
- A placebo treatment.
- Historical controls.
- Systematic alternation of treatments.
- Non-randomized concurrent controls.
Q3. Who is blinded in a double-blind trial design?
- Patient and Investigator/Provider
- Investigator/Provider and Statistician
- Patient and Caregiver
- Patient and Statistician
Q4. Which of the following elements is included in claims data?
- Diagnoses and procedure codes.
- Procedure codes and prices.
- Prices and patient demographics.
- All of the above.
Q5. Which of the following is not a benefit of claims data?
- Includes physicians notes.
- Large samples.
- Includes all sources of care.
- Diagnoses and procedures.
Q6. What are DRGs used for?
- FDA approval.
- Medicare inpatient billing/payment.
- Measuring QALYs.
- Prescription drug reimbursement.
Q7. What population is covered by Medicare?
- Ages 65 and older and disabledThe working population
- Anyone
- None of the above
Q8. Which of the following is not a potential source of bias?
- Currency
- Reporting
- Detection
- Selection
Q9. Which of the following questions can a meta-analysis answer?
- What is the direction of the effect?
- What is the size of the effect?
- Is the effect consistent across studies?
- All of the above
Q10. True or False: claims data can only be used for policy research.
- True
- False
Week 03: Peer-graded Assignment: You Are The Consultant
Week 04: Methodological Approaches and Considerations Quiz Answers
Q1. If an assessment is being conducted to support the case for payment/reimbursement
who is the audience?
- The Food and Drug Administration (FDA)
- Physicians
- Insurers or Payers
- Venture capitalists
Q2. What is the denominator of the incremental cost-effectiveness ratio (ICER)?
- Indirect costs.
- Future costs.
- Benefits of the new technology.
- Difference in benefits.
Q3. True or False: Only cost-effective technologies ICERs can be graphed on the cost-effectiveness plane.
- True
- False
Q4. What is Bayes rule used for?
- Measuring quality of life (QoL).
- Randomization in a clinical trial.
- Incorporating new information to determine a probability of interest.
- Graph an ICER.
Q5. Future values of which of the following can be discounted to present value?
- Direct medical costs.
- Indirect costs.
- Quality adjusted life years (QALYs).
- All of the above.
Q6. The expected value of a health outcome is calculated by multiplying the outcome measure by what?
- Quality of Life (QoL).
- The discount rate.
- Direct costs.
- The probability of the outcome.
Q7. The results of a Monte Carlo simulation can be used to determine the information about the results of an evaluation?
- Mean and variance of the results.
- The mean result.
- The variance of the result.
- None of the above.
Q8. True or False: A Markov model allows for modeling the progression of the disease over time.
- True
- False
Q9. Which of the following is not a source of uncertainty?
- Future costs.
- Randomness in medical cost.
- Randomness in health outcomes.
- Statistical variation in results.
Q10. In a sensitivity analysis, how many variables can be tested?
- Only one
- None
- One or more
- Only two
Next Course Quiz Answers >>
Healthcare Marketplace Capstone
<< Previous Course Quiz Answers
Pharmaceutical and Medical Device Innovations
All Course Quiz Answers of Healthcare Marketplace Specialization
Course 01: Healthcare Marketplace
Course 02: Healthcare Delivery Providers
Course 03: Pharmaceutical and Medical Device Innovations
Course 04: Medical Technology and Evaluation
Course 05: Healthcare Marketplace Capstone
